Pharmacy diabetes care program: Analysis of two screening methods for undiagnosed type 2 diabetes in Australian community pharmacy

Diabetes Research and Clinical Practice

Volumn 75, Issue 3, 2007, Pages 339-347

  Krass, I ^a   Mitchell, B ^a   Clarke, P ^e   Brillant, M ^a   Dienaar, R ^b   Hughes, J ^c   Lau, P ^d   Peterson, G ^b   Stewart, K ^d   Taylor, S ^a   Wilkinson, J ^c   Armour, C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

^c CURTIN UNIVERSITY   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Case detection; Community pharmacy; Cost effectiveness; Near patient testing; Type 2 diabetes

Indexed keywords

ADULT; ARTICLE; AUSTRALIA; COST EFFECTIVENESS ANALYSIS; FEMALE; GENERAL PRACTITIONER; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT REFERRAL; PHARMACY; RISK ASSESSMENT; SCREENING;

AUSTRALIA; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HEART DISEASES; HUMANS; HYPERTENSION; MASS SCREENING; MIDDLE AGED; PHARMACIES; REFERENCE VALUES; REFERRAL AND CONSULTATION; RISK FACTORS;

EID: 33846045087     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.06.022     Document Type: Article

References (19)

1. Dunstan D.W., Zimmet P.Z., Welborn T.A., De Courten M.P., Cameron A.J., Sicree R.A., et al. The rising prevalence of diabetes and impaired glucose tolerance: The Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 25 5 (2002) 829-834
2. S. Colagiuri, P. Zimmet, A. Hepburn, R. Colagiuri, Evidence Based Guidelines for type 2 diabetes: Primary Prevention, Case Detection and Diagnosis, Canberra, Australia, Diabetes Australia and National Health and Medical Research Council. Available at http://www.nhmrc.gov.au/publications/_files/cp86.pdf. Update available at http://www.diabetesaustralia.com.au/_lib/doc_pdf/NEBG/P1/Part1-Introduction-Jul05.pdf. Last accessed 9th March 2006.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 9131 (1998) 837-853 (see comment)(erratum appears in Lancet 1999 Aug 14;354(9178):602)
4. UK Prospective Diabetes Study (UKPDS) Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 22 7 (1999) 1125-1136
5. Pharmaceutical Society of Australia, Australian Pharmacy-Primary Health Care's forgotten resource, A submission to the Review of the Role of Primary Health care in Health Promotion in Australia, Pharmaceutical Society of Australia, Canberra, July 1991.
6. Teh R., Chen T., and Krass I. Consumer perspectives of pharmacist-delivered health promotion and screening services. Int. J. Pharm. Pract. 9 (2001) 261-267
7. McElnay J., Nicholl A., and Grainger-Rousseau T. The role of community pharmacist-a survey of public opinion in N. Ireland. Int. J. Pharm. Pract. 2 (1993) 95-100
8. http://www.qcpp.com/pharmacy_standards_checklist_july04.pdf. Last accessed 9th March 2006.
9. Dietary Guidelines for Australian Adults, Department of Health and Ageing, Canberra, 1999.
10. National Physical Activity Guidelines for Australians, Department of Health and Ageing, Canberra, 1999.
11. Briggs A., Clark T., Wolstenholme J., and Clarke P. Missing ... presumed at random: cost-analysis of incomplete data. Health Econ. 12 5 (2003) 377-392
12. I. Krass, C. Armour, S. Taylor, G.M. Peterson, K. Stewart, J.M. Hughes, Pharmacy Diabetes Care Program. Final Report: University of Sydney, 2005. http://beta.guild.org.au/uploadedfiles/Research_and_Development_Grants_Program/Projects/2002-518_fr.pdf. Last accessed 31st March 2006.
13. Colagiuri S.M.D., Hussain Z.M.S.C., Zimmet P.M.D., Cameron A.M.P.H., and Shaw J.M.D. Screening for type 2 diabetes and impaired glucose metabolism: the Australian experience. Diabetes Care 27 2 (2004) 367-371
14. Engelgau M., Narayan K., and Herman W. Screening for type 2 diabetes. Diabetes Care 23 10 (2000) 1563-1580
15. Ealovega M.W., Tabaei B.P., Brandle M., Burke R., and Herman W.H. Opportunistic screening for diabetes in routine clinical practice. Diabetes Care 27 1 (2004) 9-12
16. Leiter L.A., Barr A., Belanger A., Lubin S., Ross S.A., Tildesley H.D., et al. Diabetes Screening in Canada (DIASCAN) Study: prevalence of undiagnosed diabetes and glucose intolerance in family physician offices. Diabetes Care 24 6 (2001) 1038-1043
17. Christensen J.O., Sandbaek A., Lauritzen T., and Borch-Johnsen K. Population-based stepwise screening for unrecognised type 2 diabetes is ineffective in general practice despite reliable algorithms. Diabetologia 47 9 (2004) 1566-1573
18. Zhang P., Engelgau M.M., Valdez R., Benjamin S.M., Cadwell B., and Venkat Narayan K.M. Costs of screening for pre-diabetes among U.S. adults: a comparison of different screening strategies. Diabetes Care 26 9 (2003) 2536-2542
19. Adriaanse M.C., Snoek F.J., Dekker J.M., Spijkerman A.M.W., Nijpels G., van der Ploeg H.M., et al. Perceived risk for Type 2 diabetes in participants in a stepwise population-screening programme. Diabet. Med. 20 3 (2003) 210-215